Pharmasmart completes initial testing phase for screening unit
ROCHESTER, N.Y. — PharmaSmart's PS2000 (D)estination completed its first alpha test inside a regional grocer, the company announced. Preliminary survey results received from the patients testing the unit inside the pharmacy reported that ease of use, ease of use, multi-biometric features, patented cuff size, virtual pharmacist and interoperability with pharmacy systems as the product's best features.
The company also said that the pharmacy staff overseeing the testing provided excellent anecdotal feedback regarding clinical features and benefit to healthcare objectives of their patients at point of care.
The company is targeting commercialization in late 2014 or early 2015. The PS2000 (D)estination will be showcased in booth #1727 at NACDS TSE.
FDA approves GSK’s Arnuity Ellipta
LONDON — GlaxoSmithKline announced FDA approval for Arnuity Ellipta (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid medicine for the treatment of asthma in patients 12 years of age and older.
"The approval of Arnuity Ellipta is an important development for GSK and our expanding respiratory portfolio. It is the first asthma treatment from our new portfolio to have gained approval in the US and enables us to begin expanding the range of medicines that we offer to physicians and appropriate patients," said Darrell Baker, SVP and head, GSK global respiratory franchise.
The approved dosage strengths are 100 mcg and 200 mcg. Arnuity is delivered by the dry powder inhaler Ellipta, which is also used across a range of respiratory medications in GSK's portfolio.
Iconic brands stage a comeback
There are a number of growth drivers across the digestives space, starting with the biggest proton-pump inhibitor to make its way from behind the pharmacy bench to over-the-counter aisles since the original “Purple Pill” was switched in 2003. Once Procter & Gamble switched Prilosec OTC, it became one of the best-selling nonprescription medicines out of all categories. And now that Pfizer is bringing to OTC the $6 billion in prescription business tied to what is now known as the “Purple Pill,” Nexium, there’s no reason to think the latest PPI may soon stake its claim as one of the largest OTC brands.
(For the complete category review, including data, click here.)
But there are other iconic digestive brands making a resurgence in the space. Bayer has boosted sales of Alka Seltzer to $16 million, up 580.5%, with the introduction of Alka Seltzer Fruit Chews. Similarly, the company has increased sales of its Phillips Fiber Good brand with the introduction of a gummy line with sales of $6.3 million, up 2,603.1%.